Passage Bio is a genetic medicines company focused on developing a deep pipeline of adeno-associated virus (AAV) delivered therapeutics for the treatment of rare monogenic central nervous system disorders (CNS).
For more details on financing and valuation for Passage Bio, register or login.
By registering, you agree to Forge’s Terms of Use. Already registered? Log in
PASG
1.0157 as of 5/26/23
To read this article and more news on Passage Bio, register or login.
